文献速递儿科与产科急症

产前大麻使用与母亲妊娠结局

Prenatal Cannabis Use and Maternal Pregnancy Outcomes.
PubMed 文献 · JAMA Intern Med · 2024-01-01
一句话结论回顾性队列研究提示产前大麻使用与妊娠期高血压、子痫前期、孕期体重增长异常及胎盘早剥风险升高相关。

该研究为基于人群的回顾性队列研究,纳入2011年1月至2019年12月北加州妊娠≥20周并接受产前大麻使用筛查的316722次妊娠(250221名个体)。产前大麻使用定义为孕早期自我报告使用或入组产前保健时(约孕8-10周)通用毒理学筛查阳性。结果显示产前大麻使用与妊娠期高血压(aRR 1.17;95%CI 1.13-1.21)、子痫前期(aRR 1.08;95%CI 1.01-1.15)、体重增长低于指南(aRR 1.05;95%CI 1.01-1.08)和高于指南(aRR 1.09;95%CI 1.08-1.10)及胎盘早剥(aRR 1.19;95%CI 1.05-1.36)风险升高相关。仅用自我报告或仅用毒理学检测定义产前大麻使用时结果模式相似。作者认为需继续研究大麻使用特征(如剂量、方式、时机)是否调节这些关联。

要点

  • 产前大麻使用与妊娠期高血压风险升高相关(aRR 1.17;95%CI 1.13-1.21)。
  • 产前大麻使用与子痫前期风险升高相关(aRR 1.08;95%CI 1.01-1.15)。
  • 产前大麻使用与体重增长低于(aRR 1.05;95%CI 1.01-1.08)和高于(aRR 1.09;95%CI 1.08-1.10)指南相关。
  • 产前大麻使用与胎盘早剥风险升高相关(aRR 1.19;95%CI 1.05-1.36)。
  • 仅用自我报告或仅用毒理学检测定义产前大麻使用时,结果模式相似。

适用人群与场景

  • 2011年1月至2019年12月北加州妊娠≥20周并接受产前大麻使用筛查的妊娠。

诊断标准与关键阈值

  • 产前大麻使用:孕早期自我报告使用或入组产前保健时(约孕8-10周)通用毒理学筛查阳性。

研究设计与关键结果

  • 研究类型:基于人群的回顾性队列研究;样本量:316722次妊娠(250221名个体);人群:2011年1月至2019年12月北加州妊娠≥20周并接受产前大麻使用筛查者,平均(SD)年龄30.6(5.4)岁;26.5%亚裔/太平洋岛民、6.3%黑人、26.3%西班牙裔、37.4%白人。
  • 暴露:产前大麻使用;6.3%筛查阳性;自我报告阳性2.9%,毒理学检测阳性5.3%,两者均阳性1.8%;使用频率:每日0.6%、每周0.7%、每月或更少1.5%、未知3.4%。
  • 主要终点结果:产前大麻使用与妊娠期高血压(aRR 1.17;95%CI 1.13-1.21)、子痫前期(aRR 1.08;95%CI 1.01-1.15)、体重增长低于指南(aRR 1.05;95%CI 1.01-1.08)、体重增长高于指南(aRR 1.09;95%CI 1.08-1.10)及胎盘早剥(aRR 1.19;95%CI 1.05-1.36)风险升高相关。
  • 仅用自我报告或仅用毒理学检测定义产前大麻使用时,结果模式相似;产前大麻使用频率与结局的关联因结局而异。

证据类型、等级与局限

  • 证据类型:基于人群的回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,产前大麻使用与妊娠期若干不良母亲健康结局相关;需继续研究大麻使用特征(如剂量、方式、时机)是否调节这些关联。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Many studies have evaluated whether in utero cannabis exposure is associated with fetal and neonatal outcomes, yet little is known about whether prenatal cannabis use is associated with maternal health outcomes during pregnancy.

OBJECTIVE: To evaluate whether prenatal cannabis use is associated with maternal health outcomes during pregnancy.

DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort study included pregnancies in Northern California from January 2011 to December 2019 that lasted 20 weeks or longer and were screened for prenatal cannabis use.

EXPOSURES: Prenatal cannabis use was defined as any self-reported use during early pregnancy or a positive toxicology test result based on universal screening at entrance to prenatal care (approximately 8-10 weeks' gestation). Self-reported frequency of use (daily, weekly, monthly or less, never, unknown), use defined only by self-report, and use defined only by toxicology test results were examined.

MAIN OUTCOMES AND MEASURES: Electronic health record data were used to define the following outcomes: gestational hypertension, preeclampsia, eclampsia, gestational diabetes, gestational weight gain greater and less than guidelines, placenta previa, placental abruption, placenta accreta, and severe maternal morbidity. Adjusted risk ratios (aRRs) were calculated using a modified Poisson regression.

RESULTS: The sample (n = 316 722 pregnancies; 250 221 unique individuals) included 84 039 (26.5%) Asian/Pacific Islander, 20 053 (6.3%) Black, 83 145 (26.3%) Hispanic, and 118 333 (37.4%) White individuals; the mean (SD) age was 30.6 (5.4) years. Overall, 20 053 (6.3%) screened positive for prenatal cannabis use; 2.9% were positive by self-report, 5.3% by toxicology testing, and 1.8% by both. The frequency of cannabis use was 1930 (0.6%) daily, 2345 (0.7%) weekly, 4892 (1.5%) monthly or less, and 10 886 (3.4%) unknown. Prenatal cannabis use was associated with greater risk of gestational hypertension (aRR, 1.17; 95% CI, 1.13-1.21), preeclampsia (aRR, 1.08; 95% CI, 1.01-1.15), weight gain less than (aRR, 1.05; 95% CI, 1.01-1.08) and greater than (aRR, 1.09; 95% CI, 1.08-1.10) guidelines, and placental abruption (aRR, 1.19; 95% CI, 1.05-1.36). The pattern of results was similar when defining prenatal cannabis use only by self-report or only by toxicology testing, and associations between the frequency of prenatal cannabis use and outcomes varied with outcome.

CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that prenatal cannabis use was associated with several adverse maternal health outcomes during pregnancy. Continued research is needed to understand whether characteristics of prenatal cannabis use (eg, dose, mode, and timing) moderate these associations.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Young-Wolff KC, Adams SR, Alexeeff SE, et al. Prenatal Cannabis Use and Maternal Pregnancy Outcomes. JAMA Intern Med. 2024. PMID: 39037795. doi:10.1001/jamainternmed.2024.3270

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。